Keyphrases
Late Events
100%
Leukemogenesis
100%
Tumor Heterogeneity
100%
FMS-like Tyrosine Kinase 3 (FLT3)
100%
Single-cell Analysis
100%
Internal Tandem Duplication
100%
Acute Lymphoblastic Leukemia
16%
Leukemic Cells
16%
Acute Myeloid Leukemia
16%
Acute Leukemia
16%
Cell-based
8%
Polymerase Chain Reaction
8%
Same Patient
8%
Cell Population
8%
Small Fraction
8%
Healthy Volunteers
8%
Tumor
8%
Poor Prognosis
8%
Mutation Analysis
8%
Loss of Heterozygosity
8%
Prognostic Significance
8%
DNA Analysis
8%
Targeted Therapy
8%
Newly Diagnosed
8%
Diagnostic Techniques
8%
Clinical Testing
8%
FLT3 mutation
8%
Applied Biosystems
8%
Duplication mutation
8%
Cell mutation
8%
Minor Clone
8%
Bulk DNA
8%
GeneScan
8%
Immunology and Microbiology
Myeloid
100%
Single Cell Analysis
100%
Polymerase Chain Reaction
50%
Allele
50%
Volume
50%
Normal Human
50%
Cell Population
50%
Data Analysis Software
50%
Heterozygosity
50%
Medicine and Dentistry
Receptor
100%
Leukemogenesis
100%
FMS-Like Tyrosine Kinase 3
100%
Acute Myeloid Leukemia
16%
Acute Lymphoblastic Leukemia
16%
Acute Leukemia
16%
Neoplasm
8%
Allele
8%
Cell Population
8%
Polymerase Chain Reaction
8%
Volunteer
8%
Diagnostic Procedure
8%
SEQUEST
8%
Targeted Therapy
8%
DNA Determination
8%
Heterozygosity
8%
Biochemistry, Genetics and Molecular Biology
Eicosanoid Receptor
100%
Single-Cell Analysis
100%
FMS-Like Tyrosine Kinase 3
100%
Myeloid
16%
Polymerase Chain Reaction
8%
Allele
8%
DNA Analysis
8%
Volume
8%
Normal Human
8%
Loss of Heterozygosity
8%
SEQUEST
8%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Leukemogenesis
100%
Protein Kinase Fer
100%
Acute Myeloid Leukemia
16%
Acute Lymphoblastic Leukemia
16%
Acute Leukemia
16%
Normal Human
8%
Neoplasm
8%